Clinical Trial Update: First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients [Phase 4]

View source ↗

Summary

This document provides a Phase 4 clinical trial update on first-line icotinib therapy in elderly patients with EGFR-mutated non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 4 | Status: UNKNOWN